The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Chimeric Antigen Receptor Cell Therapy Market 2024 by Company, Regions, Type and Application, Forecast to 2028
Synopsis
The Chimeric Antigen Receptor Cell Therapy market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Chimeric Antigen Receptor Cell Therapy market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Acute Leukemia accounting for % of the Chimeric Antigen Receptor Cell Therapy global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Monotherapy segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Chimeric Antigen Receptor Cell Therapy include Amgen Inc, Autolus Therapeutics Plc, Beijing Immunochina Medical Science & Technology Co Ltd, Bellicum Pharmaceuticals Inc, and Bristol-Myers Squibb Co, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Chimeric Antigen Receptor Cell Therapy market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Monotherapy
Combination Therapy
Market segment by Application, can be divided into
Acute Leukemia
Non-hodgkin's Lymphoma
Multiple Myeloma
Transplant Rejection
Other
Market segment by players, this report covers
Amgen Inc
Autolus Therapeutics Plc
Beijing Immunochina Medical Science & Technology Co Ltd
Bellicum Pharmaceuticals Inc
Bristol-Myers Squibb Co
bluebird bio Inc
CARsgen Therapeutics Ltd
Celgene Corp
Cell Medica Ltd
Cellular Biomedicine Group Inc
Celularity Inc
Celyad SA
Daiichi Sankyo Co Ltd
Fosun Pharmaceutical AG
Gilead Sciences Inc
Guangzhou Anjie Biomedical Technology Co Ltd
Hangzhou Converd Co Ltd
Hebei Senlang Biotechnology Inc Ltd
HRAIN Biotechnology Co Ltd
Juno Therapeutics Inc
Kite Pharma Inc
Nanjing Legend Biotech Co Ltd
NantKwest Inc
Nkarta Inc
Novartis AG
Ono Pharmaceutical Co Ltd
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Sorrento Therapeutics Inc
Takara Bio Inc
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Chimeric Antigen Receptor Cell Therapy product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Chimeric Antigen Receptor Cell Therapy, with revenue, gross margin and global market share of Chimeric Antigen Receptor Cell Therapy from 2019 to 2022.
Chapter 3, the Chimeric Antigen Receptor Cell Therapy competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Chimeric Antigen Receptor Cell Therapy market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Chimeric Antigen Receptor Cell Therapy research findings and conclusion, appendix and data source.
Geographical Area
Global
The Chimeric Antigen Receptor Cell Therapy market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Chimeric Antigen Receptor Cell Therapy market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Acute Leukemia accounting for % of the Chimeric Antigen Receptor Cell Therapy global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Monotherapy segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Chimeric Antigen Receptor Cell Therapy include Amgen Inc, Autolus Therapeutics Plc, Beijing Immunochina Medical Science & Technology Co Ltd, Bellicum Pharmaceuticals Inc, and Bristol-Myers Squibb Co, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Chimeric Antigen Receptor Cell Therapy market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Monotherapy
Combination Therapy
Market segment by Application, can be divided into
Acute Leukemia
Non-hodgkin's Lymphoma
Multiple Myeloma
Transplant Rejection
Other
Market segment by players, this report covers
Amgen Inc
Autolus Therapeutics Plc
Beijing Immunochina Medical Science & Technology Co Ltd
Bellicum Pharmaceuticals Inc
Bristol-Myers Squibb Co
bluebird bio Inc
CARsgen Therapeutics Ltd
Celgene Corp
Cell Medica Ltd
Cellular Biomedicine Group Inc
Celularity Inc
Celyad SA
Daiichi Sankyo Co Ltd
Fosun Pharmaceutical AG
Gilead Sciences Inc
Guangzhou Anjie Biomedical Technology Co Ltd
Hangzhou Converd Co Ltd
Hebei Senlang Biotechnology Inc Ltd
HRAIN Biotechnology Co Ltd
Juno Therapeutics Inc
Kite Pharma Inc
Nanjing Legend Biotech Co Ltd
NantKwest Inc
Nkarta Inc
Novartis AG
Ono Pharmaceutical Co Ltd
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Sorrento Therapeutics Inc
Takara Bio Inc
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Chimeric Antigen Receptor Cell Therapy product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Chimeric Antigen Receptor Cell Therapy, with revenue, gross margin and global market share of Chimeric Antigen Receptor Cell Therapy from 2019 to 2022.
Chapter 3, the Chimeric Antigen Receptor Cell Therapy competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Chimeric Antigen Receptor Cell Therapy market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Chimeric Antigen Receptor Cell Therapy research findings and conclusion, appendix and data source.
Geographical Area
Global
Index1 Market Overview
1.1 Product Overview and Scope of Chimeric Antigen Receptor Cell Therapy
1.2 Classification of Chimeric Antigen Receptor Cell Therapy by Type
1.2.1 Overview: Global Chimeric Antigen Receptor Cell Therapy Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Chimeric Antigen Receptor Cell Therapy Revenue Market Share by Type in 2021
1.2.3 Monotherapy
1.2.4 Combination Therapy
1.3 Global Chimeric Antigen Receptor Cell Therapy Market by Application
1.3.1 Overview: Global Chimeric Antigen Receptor Cell Therapy Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Acute Leukemia
1.3.3 Non-hodgkin's Lymphoma
1.3.4 Multiple Myeloma
1.3.5 Transplant Rejection
1.3.6 Other
1.4 Global Chimeric Antigen Receptor Cell Therapy Market Size & Forecast
1.5 Global Chimeric Antigen Receptor Cell Therapy Market Size and Forecast by Region
1.5.1 Global Chimeric Antigen Receptor Cell Therapy Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Chimeric Antigen Receptor Cell Therapy Market Size by Region, (2017-2022)
1.5.3 North America Chimeric Antigen Receptor Cell Therapy Market Size and Prospect (2017-2028)
1.5.4 Europe Chimeric Antigen Receptor Cell Therapy Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Chimeric Antigen Receptor Cell Therapy Market Size and Prospect (2017-2028)
1.5.6 South America Chimeric Antigen Receptor Cell Therapy Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Chimeric Antigen Receptor Cell Therapy Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Chimeric Antigen Receptor Cell Therapy Market Drivers
1.6.2 Chimeric Antigen Receptor Cell Therapy Market Restraints
1.6.3 Chimeric Antigen Receptor Cell Therapy Trends Analysis
2 Company Profiles
2.1 Amgen Inc
2.1.1 Amgen Inc Details
2.1.2 Amgen Inc Major Business
2.1.3 Amgen Inc Chimeric Antigen Receptor Cell Therapy Product and Solutions
2.1.4 Amgen Inc Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Amgen Inc Recent Developments and Future Plans
2.2 Autolus Therapeutics Plc
2.2.1 Autolus Therapeutics Plc Details
2.2.2 Autolus Therapeutics Plc Major Business
2.2.3 Autolus Therapeutics Plc Chimeric Antigen Receptor Cell Therapy Product and Solutions
2.2.4 Autolus Therapeutics Plc Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Autolus Therapeutics Plc Recent Developments and Future Plans
2.3 Beijing Immunochina Medical Science & Technology Co Ltd
2.3.1 Beijing Immunochina Medical Science & Technology Co Ltd Details
2.3.2 Beijing Immunochina Medical Science & Technology Co Ltd Major Business
2.3.3 Beijing Immunochina Medical Science & Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Product and Solutions
2.3.4 Beijing Immunochina Medical Science & Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Beijing Immunochina Medical Science & Technology Co Ltd Recent Developments and Future Plans
2.4 Bellicum Pharmaceuticals Inc
2.4.1 Bellicum Pharmaceuticals Inc Details
2.4.2 Bellicum Pharmaceuticals Inc Major Business
2.4.3 Bellicum Pharmaceuticals Inc Chimeric Antigen Receptor Cell Therapy Product and Solutions
2.4.4 Bellicum Pharmaceuticals Inc Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Bellicum Pharmaceuticals Inc Recent Developments and Future Plans
2.5 Bristol-Myers Squibb Co
2.5.1 Bristol-Myers Squibb Co Details
2.5.2 Bristol-Myers Squibb Co Major Business
2.5.3 Bristol-Myers Squibb Co Chimeric Antigen Receptor Cell Therapy Product and Solutions
2.5.4 Bristol-Myers Squibb Co Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Bristol-Myers Squibb Co Recent Developments and Future Plans
2.6 bluebird bio Inc
2.6.1 bluebird bio Inc Details
2.6.2 bluebird bio Inc Major Business
2.6.3 bluebird bio Inc Chimeric Antigen Receptor Cell Therapy Product and Solutions
2.6.4 bluebird bio Inc Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 bluebird bio Inc Recent Developments and Future Plans
2.7 CARsgen Therapeutics Ltd
2.7.1 CARsgen Therapeutics Ltd Details
2.7.2 CARsgen Therapeutics Ltd Major Business
2.7.3 CARsgen Therapeutics Ltd Chimeric Antigen Receptor Cell Therapy Product and Solutions
2.7.4 CARsgen Therapeutics Ltd Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 CARsgen Therapeutics Ltd Recent Developments and Future Plans
2.8 Celgene Corp
2.8.1 Celgene Corp Details
2.8.2 Celgene Corp Major Business
2.8.3 Celgene Corp Chimeric Antigen Receptor Cell Therapy Product and Solutions
2.8.4 Celgene Corp Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Celgene Corp Recent Developments and Future Plans
2.9 Cell Medica Ltd
2.9.1 Cell Medica Ltd Details
2.9.2 Cell Medica Ltd Major Business
2.9.3 Cell Medica Ltd Chimeric Antigen Receptor Cell Therapy Product and Solutions
2.9.4 Cell Medica Ltd Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Cell Medica Ltd Recent Developments and Future Plans
2.10 Cellular Biomedicine Group Inc
2.10.1 Cellular Biomedicine Group Inc Details
2.10.2 Cellular Biomedicine Group Inc Major Business
2.10.3 Cellular Biomedicine Group Inc Chimeric Antigen Receptor Cell Therapy Product and Solutions
2.10.4 Cellular Biomedicine Group Inc Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 Cellular Biomedicine Group Inc Recent Developments and Future Plans
2.11 Celularity Inc
2.11.1 Celularity Inc Details
2.11.2 Celularity Inc Major Business
2.11.3 Celularity Inc Chimeric Antigen Receptor Cell Therapy Product and Solutions
2.11.4 Celularity Inc Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11.5 Celularity Inc Recent Developments and Future Plans
2.12 Celyad SA
2.12.1 Celyad SA Details
2.12.2 Celyad SA Major Business
2.12.3 Celyad SA Chimeric Antigen Receptor Cell Therapy Product and Solutions
2.12.4 Celyad SA Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12.5 Celyad SA Recent Developments and Future Plans
2.13 Daiichi Sankyo Co Ltd
2.13.1 Daiichi Sankyo Co Ltd Details
2.13.2 Daiichi Sankyo Co Ltd Major Business
2.13.3 Daiichi Sankyo Co Ltd Chimeric Antigen Receptor Cell Therapy Product and Solutions
2.13.4 Daiichi Sankyo Co Ltd Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13.5 Daiichi Sankyo Co Ltd Recent Developments and Future Plans
2.14 Fosun Pharmaceutical AG
2.14.1 Fosun Pharmaceutical AG Details
2.14.2 Fosun Pharmaceutical AG Major Business
2.14.3 Fosun Pharmaceutical AG Chimeric Antigen Receptor Cell Therapy Product and Solutions
2.14.4 Fosun Pharmaceutical AG Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14.5 Fosun Pharmaceutical AG Recent Developments and Future Plans
2.15 Gilead Sciences Inc
2.15.1 Gilead Sciences Inc Details
2.15.2 Gilead Sciences Inc Major Business
2.15.3 Gilead Sciences Inc Chimeric Antigen Receptor Cell Therapy Product and Solutions
2.15.4 Gilead Sciences Inc Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.15.5 Gilead Sciences Inc Recent Developments and Future Plans
2.16 Guangzhou Anjie Biomedical Technology Co Ltd
2.16.1 Guangzhou Anjie Biomedical Technology Co Ltd Details
2.16.2 Guangzhou Anjie Biomedical Technology Co Ltd Major Business
2.16.3 Guangzhou Anjie Biomedical Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Product and Solutions
2.16.4 Guangzhou Anjie Biomedical Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.16.5 Guangzhou Anjie Biomedical Technology Co Ltd Recent Developments and Future Plans
2.17 Hangzhou Converd Co Ltd
2.17.1 Hangzhou Converd Co Ltd Details
2.17.2 Hangzhou Converd Co Ltd Major Business
2.17.3 Hangzhou Converd Co Ltd Chimeric Antigen Receptor Cell Therapy Product and Solutions
2.17.4 Hangzhou Converd Co Ltd Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.17.5 Hangzhou Converd Co Ltd Recent Developments and Future Plans
2.18 Hebei Senlang Biotechnology Inc Ltd
2.18.1 Hebei Senlang Biotechnology Inc Ltd Details
2.18.2 Hebei Senlang Biotechnology Inc Ltd Major Business
2.18.3 Hebei Senlang Biotechnology Inc Ltd Chimeric Antigen Receptor Cell Therapy Product and Solutions
2.18.4 Hebei Senlang Biotechnology Inc Ltd Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.18.5 Hebei Senlang Biotechnology Inc Ltd Recent Developments and Future Plans
2.19 HRAIN Biotechnology Co Ltd
2.19.1 HRAIN Biotechnology Co Ltd Details
2.19.2 HRAIN Biotechnology Co Ltd Major Business
2.19.3 HRAIN Biotechnology Co Ltd Chimeric Antigen Receptor Cell Therapy Product and Solutions
2.19.4 HRAIN Biotechnology Co Ltd Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.19.5 HRAIN Biotechnology Co Ltd Recent Developments and Future Plans
2.20 Juno Therapeutics Inc
2.20.1 Juno Therapeutics Inc Details
2.20.2 Juno Therapeutics Inc Major Business
2.20.3 Juno Therapeutics Inc Chimeric Antigen Receptor Cell Therapy Product and Solutions
2.20.4 Juno Therapeutics Inc Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.20.5 Juno Therapeutics Inc Recent Developments and Future Plans
2.21 Kite Pharma Inc
2.21.1 Kite Pharma Inc Details
2.21.2 Kite Pharma Inc Major Business
2.21.3 Kite Pharma Inc Chimeric Antigen Receptor Cell Therapy Product and Solutions
2.21.4 Kite Pharma Inc Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.21.5 Kite Pharma Inc Recent Developments and Future Plans
2.22 Nanjing Legend Biotech Co Ltd
2.22.1 Nanjing Legend Biotech Co Ltd Details
2.22.2 Nanjing Legend Biotech Co Ltd Major Business
2.22.3 Nanjing Legend Biotech Co Ltd Chimeric Antigen Receptor Cell Therapy Product and Solutions
2.22.4 Nanjing Legend Biotech Co Ltd Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.22.5 Nanjing Legend Biotech Co Ltd Recent Developments and Future Plans
2.23 NantKwest Inc
2.23.1 NantKwest Inc Details
2.23.2 NantKwest Inc Major Business
2.23.3 NantKwest Inc Chimeric Antigen Receptor Cell Therapy Product and Solutions
2.23.4 NantKwest Inc Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.23.5 NantKwest Inc Recent Developments and Future Plans
2.24 Nkarta Inc
2.24.1 Nkarta Inc Details
2.24.2 Nkarta Inc Major Business
2.24.3 Nkarta Inc Chimeric Antigen Receptor Cell Therapy Product and Solutions
2.24.4 Nkarta Inc Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.24.5 Nkarta Inc Recent Developments and Future Plans
2.25 Novartis AG
2.25.1 Novartis AG Details
2.25.2 Novartis AG Major Business
2.25.3 Novartis AG Chimeric Antigen Receptor Cell Therapy Product and Solutions
2.25.4 Novartis AG Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.25.5 Novartis AG Recent Developments and Future Plans
2.26 Ono Pharmaceutical Co Ltd
2.26.1 Ono Pharmaceutical Co Ltd Details
2.26.2 Ono Pharmaceutical Co Ltd Major Business
2.26.3 Ono Pharmaceutical Co Ltd Chimeric Antigen Receptor Cell Therapy Product and Solutions
2.26.4 Ono Pharmaceutical Co Ltd Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.26.5 Ono Pharmaceutical Co Ltd Recent Developments and Future Plans
2.27 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
2.27.1 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Details
2.27.2 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Major Business
2.27.3 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Product and Solutions
2.27.4 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.27.5 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Recent Developments and Future Plans
2.28 Sorrento Therapeutics Inc
2.28.1 Sorrento Therapeutics Inc Details
2.28.2 Sorrento Therapeutics Inc Major Business
2.28.3 Sorrento Therapeutics Inc Chimeric Antigen Receptor Cell Therapy Product and Solutions
2.28.4 Sorrento Therapeutics Inc Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.28.5 Sorrento Therapeutics Inc Recent Developments and Future Plans
2.29 Takara Bio Inc
2.29.1 Takara Bio Inc Details
2.29.2 Takara Bio Inc Major Business
2.29.3 Takara Bio Inc Chimeric Antigen Receptor Cell Therapy Product and Solutions
2.29.4 Takara Bio Inc Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.29.5 Takara Bio Inc Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Chimeric Antigen Receptor Cell Therapy Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Chimeric Antigen Receptor Cell Therapy Players Market Share in 2021
3.2.2 Top 10 Chimeric Antigen Receptor Cell Therapy Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Chimeric Antigen Receptor Cell Therapy Players Head Office, Products and Services Provided
3.4 Chimeric Antigen Receptor Cell Therapy Mergers & Acquisitions
3.5 Chimeric Antigen Receptor Cell Therapy New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Chimeric Antigen Receptor Cell Therapy Revenue and Market Share by Type (2017-2022)
4.2 Global Chimeric Antigen Receptor Cell Therapy Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5.1 Global Chimeric Antigen Receptor Cell Therapy Revenue Market Share by Application (2017-2022)
5.2 Global Chimeric Antigen Receptor Cell Therapy Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6.1 North America Chimeric Antigen Receptor Cell Therapy Revenue by Type (2017-2028)
6.2 North America Chimeric Antigen Receptor Cell Therapy Revenue by Application (2017-2028)
6.3 North America Chimeric Antigen Receptor Cell Therapy Market Size by Country
6.3.1 North America Chimeric Antigen Receptor Cell Therapy Revenue by Country (2017-2028)
6.3.2 United States Chimeric Antigen Receptor Cell Therapy Market Size and Forecast (2017-2028)
6.3.3 Canada Chimeric Antigen Receptor Cell Therapy Market Size and Forecast (2017-2028)
6.3.4 Mexico Chimeric Antigen Receptor Cell Therapy Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7.1 Europe Chimeric Antigen Receptor Cell Therapy Revenue by Type (2017-2028)
7.2 Europe Chimeric Antigen Receptor Cell Therapy Revenue by Application (2017-2028)
7.3 Europe Chimeric Antigen Receptor Cell Therapy Market Size by Country
7.3.1 Europe Chimeric Antigen Receptor Cell Therapy Revenue by Country (2017-2028)
7.3.2 Germany Chimeric Antigen Receptor Cell Therapy Market Size and Forecast (2017-2028)
7.3.3 France Chimeric Antigen Receptor Cell Therapy Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Chimeric Antigen Receptor Cell Therapy Market Size and Forecast (2017-2028)
7.3.5 Russia Chimeric Antigen Receptor Cell Therapy Market Size and Forecast (2017-2028)
7.3.6 Italy Chimeric Antigen Receptor Cell Therapy Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Chimeric Antigen Receptor Cell Therapy Revenue by Type (2017-2028)
8.2 Asia-Pacific Chimeric Antigen Receptor Cell Therapy Revenue by Application (2017-2028)
8.3 Asia-Pacific Chimeric Antigen Receptor Cell Therapy Market Size by Region
8.3.1 Asia-Pacific Chimeric Antigen Receptor Cell Therapy Revenue by Region (2017-2028)
8.3.2 China Chimeric Antigen Receptor Cell Therapy Market Size and Forecast (2017-2028)
8.3.3 Japan Chimeric Antigen Receptor Cell Therapy Market Size and Forecast (2017-2028)
8.3.4 South Korea Chimeric Antigen Receptor Cell Therapy Market Size and Forecast (2017-2028)
8.3.5 India Chimeric Antigen Receptor Cell Therapy Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Chimeric Antigen Receptor Cell Therapy Market Size and Forecast (2017-2028)
8.3.7 Australia Chimeric Antigen Receptor Cell Therapy Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9.1 South America Chimeric Antigen Receptor Cell Therapy Revenue by Type (2017-2028)
9.2 South America Chimeric Antigen Receptor Cell Therapy Revenue by Application (2017-2028)
9.3 South America Chimeric Antigen Receptor Cell Therapy Market Size by Country
9.3.1 South America Chimeric Antigen Receptor Cell Therapy Revenue by Country (2017-2028)
9.3.2 Brazil Chimeric Antigen Receptor Cell Therapy Market Size and Forecast (2017-2028)
9.3.3 Argentina Chimeric Antigen Receptor Cell Therapy Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Chimeric Antigen Receptor Cell Therapy Revenue by Type (2017-2028)
10.2 Middle East & Africa Chimeric Antigen Receptor Cell Therapy Revenue by Application (2017-2028)
10.3 Middle East & Africa Chimeric Antigen Receptor Cell Therapy Market Size by Country
10.3.1 Middle East & Africa Chimeric Antigen Receptor Cell Therapy Revenue by Country (2017-2028)
10.3.2 Turkey Chimeric Antigen Receptor Cell Therapy Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Chimeric Antigen Receptor Cell Therapy Market Size and Forecast (2017-2028)
10.3.4 UAE Chimeric Antigen Receptor Cell Therapy Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of TablesList of Tables
Table 1. Global Chimeric Antigen Receptor Cell Therapy Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Chimeric Antigen Receptor Cell Therapy Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Chimeric Antigen Receptor Cell Therapy Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Chimeric Antigen Receptor Cell Therapy Revenue (USD Million) by Region (2017-2022)
Table 5. Global Chimeric Antigen Receptor Cell Therapy Revenue Market Share by Region (2023-2028)
Table 6. Amgen Inc Corporate Information, Head Office, and Major Competitors
Table 7. Amgen Inc Major Business
Table 8. Amgen Inc Chimeric Antigen Receptor Cell Therapy Product and Solutions
Table 9. Amgen Inc Chimeric Antigen Receptor Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Autolus Therapeutics Plc Corporate Information, Head Office, and Major Competitors
Table 11. Autolus Therapeutics Plc Major Business
Table 12. Autolus Therapeutics Plc Chimeric Antigen Receptor Cell Therapy Product and Solutions
Table 13. Autolus Therapeutics Plc Chimeric Antigen Receptor Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Beijing Immunochina Medical Science & Technology Co Ltd Corporate Information, Head Office, and Major Competitors
Table 15. Beijing Immunochina Medical Science & Technology Co Ltd Major Business
Table 16. Beijing Immunochina Medical Science & Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Product and Solutions
Table 17. Beijing Immunochina Medical Science & Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Bellicum Pharmaceuticals Inc Corporate Information, Head Office, and Major Competitors
Table 19. Bellicum Pharmaceuticals Inc Major Business
Table 20. Bellicum Pharmaceuticals Inc Chimeric Antigen Receptor Cell Therapy Product and Solutions
Table 21. Bellicum Pharmaceuticals Inc Chimeric Antigen Receptor Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Bristol-Myers Squibb Co Corporate Information, Head Office, and Major Competitors
Table 23. Bristol-Myers Squibb Co Major Business
Table 24. Bristol-Myers Squibb Co Chimeric Antigen Receptor Cell Therapy Product and Solutions
Table 25. Bristol-Myers Squibb Co Chimeric Antigen Receptor Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. bluebird bio Inc Corporate Information, Head Office, and Major Competitors
Table 27. bluebird bio Inc Major Business
Table 28. bluebird bio Inc Chimeric Antigen Receptor Cell Therapy Product and Solutions
Table 29. bluebird bio Inc Chimeric Antigen Receptor Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. CARsgen Therapeutics Ltd Corporate Information, Head Office, and Major Competitors
Table 31. CARsgen Therapeutics Ltd Major Business
Table 32. CARsgen Therapeutics Ltd Chimeric Antigen Receptor Cell Therapy Product and Solutions
Table 33. CARsgen Therapeutics Ltd Chimeric Antigen Receptor Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Celgene Corp Corporate Information, Head Office, and Major Competitors
Table 35. Celgene Corp Major Business
Table 36. Celgene Corp Chimeric Antigen Receptor Cell Therapy Product and Solutions
Table 37. Celgene Corp Chimeric Antigen Receptor Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Cell Medica Ltd Corporate Information, Head Office, and Major Competitors
Table 39. Cell Medica Ltd Major Business
Table 40. Cell Medica Ltd Chimeric Antigen Receptor Cell Therapy Product and Solutions
Table 41. Cell Medica Ltd Chimeric Antigen Receptor Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Cellular Biomedicine Group Inc Corporate Information, Head Office, and Major Competitors
Table 43. Cellular Biomedicine Group Inc Major Business
Table 44. Cellular Biomedicine Group Inc Chimeric Antigen Receptor Cell Therapy Product and Solutions
Table 45. Cellular Biomedicine Group Inc Chimeric Antigen Receptor Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. Celularity Inc Corporate Information, Head Office, and Major Competitors
Table 47. Celularity Inc Major Business
Table 48. Celularity Inc Chimeric Antigen Receptor Cell Therapy Product and Solutions
Table 49. Celularity Inc Chimeric Antigen Receptor Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 50. Celyad SA Corporate Information, Head Office, and Major Competitors
Table 51. Celyad SA Major Business
Table 52. Celyad SA Chimeric Antigen Receptor Cell Therapy Product and Solutions
Table 53. Celyad SA Chimeric Antigen Receptor Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 54. Daiichi Sankyo Co Ltd Corporate Information, Head Office, and Major Competitors
Table 55. Daiichi Sankyo Co Ltd Major Business
Table 56. Daiichi Sankyo Co Ltd Chimeric Antigen Receptor Cell Therapy Product and Solutions
Table 57. Daiichi Sankyo Co Ltd Chimeric Antigen Receptor Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 58. Fosun Pharmaceutical AG Corporate Information, Head Office, and Major Competitors
Table 59. Fosun Pharmaceutical AG Major Business
Table 60. Fosun Pharmaceutical AG Chimeric Antigen Receptor Cell Therapy Product and Solutions
Table 61. Fosun Pharmaceutical AG Chimeric Antigen Receptor Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 62. Gilead Sciences Inc Corporate Information, Head Office, and Major Competitors
Table 63. Gilead Sciences Inc Major Business
Table 64. Gilead Sciences Inc Chimeric Antigen Receptor Cell Therapy Product and Solutions
Table 65. Gilead Sciences Inc Chimeric Antigen Receptor Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 66. Guangzhou Anjie Biomedical Technology Co Ltd Corporate Information, Head Office, and Major Competitors
Table 67. Guangzhou Anjie Biomedical Technology Co Ltd Major Business
Table 68. Guangzhou Anjie Biomedical Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Product and Solutions
Table 69. Guangzhou Anjie Biomedical Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 70. Hangzhou Converd Co Ltd Corporate Information, Head Office, and Major Competitors
Table 71. Hangzhou Converd Co Ltd Major Business
Table 72. Hangzhou Converd Co Ltd Chimeric Antigen Receptor Cell Therapy Product and Solutions
Table 73. Hangzhou Converd Co Ltd Chimeric Antigen Receptor Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 74. Hebei Senlang Biotechnology Inc Ltd Corporate Information, Head Office, and Major Competitors
Table 75. Hebei Senlang Biotechnology Inc Ltd Major Business
Table 76. Hebei Senlang Biotechnology Inc Ltd Chimeric Antigen Receptor Cell Therapy Product and Solutions
Table 77. Hebei Senlang Biotechnology Inc Ltd Chimeric Antigen Receptor Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 78. HRAIN Biotechnology Co Ltd Corporate Information, Head Office, and Major Competitors
Table 79. HRAIN Biotechnology Co Ltd Major Business
Table 80. HRAIN Biotechnology Co Ltd Chimeric Antigen Receptor Cell Therapy Product and Solutions
Table 81. HRAIN Biotechnology Co Ltd Chimeric Antigen Receptor Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 82. Juno Therapeutics Inc Corporate Information, Head Office, and Major Competitors
Table 83. Juno Therapeutics Inc Major Business
Table 84. Juno Therapeutics Inc Chimeric Antigen Receptor Cell Therapy Product and Solutions
Table 85. Juno Therapeutics Inc Chimeric Antigen Receptor Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 86. Kite Pharma Inc Corporate Information, Head Office, and Major Competitors
Table 87. Kite Pharma Inc Major Business
Table 88. Kite Pharma Inc Chimeric Antigen Receptor Cell Therapy Product and Solutions
Table 89. Kite Pharma Inc Chimeric Antigen Receptor Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 90. Nanjing Legend Biotech Co Ltd Corporate Information, Head Office, and Major Competitors
Table 91. Nanjing Legend Biotech Co Ltd Major Business
Table 92. Nanjing Legend Biotech Co Ltd Chimeric Antigen Receptor Cell Therapy Product and Solutions
Table 93. Nanjing Legend Biotech Co Ltd Chimeric Antigen Receptor Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 94. NantKwest Inc Corporate Information, Head Office, and Major Competitors
Table 95. NantKwest Inc Major Business
Table 96. NantKwest Inc Chimeric Antigen Receptor Cell Therapy Product and Solutions
Table 97. NantKwest Inc Chimeric Antigen Receptor Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 98. Nkarta Inc Corporate Information, Head Office, and Major Competitors
Table 99. Nkarta Inc Major Business
Table 100. Nkarta Inc Chimeric Antigen Receptor Cell Therapy Product and Solutions
Table 101. Nkarta Inc Chimeric Antigen Receptor Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 102. Novartis AG Corporate Information, Head Office, and Major Competitors
Table 103. Novartis AG Major Business
Table 104. Novartis AG Chimeric Antigen Receptor Cell Therapy Product and Solutions
Table 105. Novartis AG Chimeric Antigen Receptor Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 106. Ono Pharmaceutical Co Ltd Corporate Information, Head Office, and Major Competitors
Table 107. Ono Pharmaceutical Co Ltd Major Business
Table 108. Ono Pharmaceutical Co Ltd Chimeric Antigen Receptor Cell Therapy Product and Solutions
Table 109. Ono Pharmaceutical Co Ltd Chimeric Antigen Receptor Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 110. Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Corporate Information, Head Office, and Major Competitors
Table 111. Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Major Business
Table 112. Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Product and Solutions
Table 113. Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 114. Sorrento Therapeutics Inc Corporate Information, Head Office, and Major Competitors
Table 115. Sorrento Therapeutics Inc Major Business
Table 116. Sorrento Therapeutics Inc Chimeric Antigen Receptor Cell Therapy Product and Solutions
Table 117. Sorrento Therapeutics Inc Chimeric Antigen Receptor Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 118. Takara Bio Inc Corporate Information, Head Office, and Major Competitors
Table 119. Takara Bio Inc Major Business
Table 120. Takara Bio Inc Chimeric Antigen Receptor Cell Therapy Product and Solutions
Table 121. Takara Bio Inc Chimeric Antigen Receptor Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 122. Global Chimeric Antigen Receptor Cell Therapy Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 123. Global Chimeric Antigen Receptor Cell Therapy Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 124. Breakdown of Chimeric Antigen Receptor Cell Therapy by Company Type (Tier 1, Tier 2 and Tier 3)
Table 125. Chimeric Antigen Receptor Cell Therapy Players Head Office, Products and Services Provided
Table 126. Chimeric Antigen Receptor Cell Therapy Mergers & Acquisitions in the Past Five Years
Table 127. Chimeric Antigen Receptor Cell Therapy New Entrants and Expansion Plans
Table 128. Global Chimeric Antigen Receptor Cell Therapy Revenue (USD Million) by Type (2017-2022)
Table 129. Global Chimeric Antigen Receptor Cell Therapy Revenue Share by Type (2017-2022)
Table 130. Global Chimeric Antigen Receptor Cell Therapy Revenue Forecast by Type (2023-2028)
Table 131. Global Chimeric Antigen Receptor Cell Therapy Revenue by Application (2017-2022)
Table 132. Global Chimeric Antigen Receptor Cell Therapy Revenue Forecast by Application (2023-2028)
Table 133. North America Chimeric Antigen Receptor Cell Therapy Revenue by Type (2017-2022) & (USD Million)
Table 134. North America Chimeric Antigen Receptor Cell Therapy Revenue by Type (2023-2028) & (USD Million)
Table 135. North America Chimeric Antigen Receptor Cell Therapy Revenue by Application (2017-2022) & (USD Million)
Table 136. North America Chimeric Antigen Receptor Cell Therapy Revenue by Application (2023-2028) & (USD Million)
Table 137. North America Chimeric Antigen Receptor Cell Therapy Revenue by Country (2017-2022) & (USD Million)
Table 138. North America Chimeric Antigen Receptor Cell Therapy Revenue by Country (2023-2028) & (USD Million)
Table 139. Europe Chimeric Antigen Receptor Cell Therapy Revenue by Type (2017-2022) & (USD Million)
Table 140. Europe Chimeric Antigen Receptor Cell Therapy Revenue by Type (2023-2028) & (USD Million)
Table 141. Europe Chimeric Antigen Receptor Cell Therapy Revenue by Application (2017-2022) & (USD Million)
Table 142. Europe Chimeric Antigen Receptor Cell Therapy Revenue by Application (2023-2028) & (USD Million)
Table 143. Europe Chimeric Antigen Receptor Cell Therapy Revenue by Country (2017-2022) & (USD Million)
Table 144. Europe Chimeric Antigen Receptor Cell Therapy Revenue by Country (2023-2028) & (USD Million)
Table 145. Asia-Pacific Chimeric Antigen Receptor Cell Therapy Revenue by Type (2017-2022) & (USD Million)
Table 146. Asia-Pacific Chimeric Antigen Receptor Cell Therapy Revenue by Type (2023-2028) & (USD Million)
Table 147. Asia-Pacific Chimeric Antigen Receptor Cell Therapy Revenue by Application (2017-2022) & (USD Million)
Table 148. Asia-Pacific Chimeric Antigen Receptor Cell Therapy Revenue by Application (2023-2028) & (USD Million)
Table 149. Asia-Pacific Chimeric Antigen Receptor Cell Therapy Revenue by Region (2017-2022) & (USD Million)
Table 150. Asia-Pacific Chimeric Antigen Receptor Cell Therapy Revenue by Region (2023-2028) & (USD Million)
Table 151. South America Chimeric Antigen Receptor Cell Therapy Revenue by Type (2017-2022) & (USD Million)
Table 152. South America Chimeric Antigen Receptor Cell Therapy Revenue by Type (2023-2028) & (USD Million)
Table 153. South America Chimeric Antigen Receptor Cell Therapy Revenue by Application (2017-2022) & (USD Million)
Table 154. South America Chimeric Antigen Receptor Cell Therapy Revenue by Application (2023-2028) & (USD Million)
Table 155. South America Chimeric Antigen Receptor Cell Therapy Revenue by Country (2017-2022) & (USD Million)
Table 156. South America Chimeric Antigen Receptor Cell Therapy Revenue by Country (2023-2028) & (USD Million)
Table 157. Middle East & Africa Chimeric Antigen Receptor Cell Therapy Revenue by Type (2017-2022) & (USD Million)
Table 158. Middle East & Africa Chimeric Antigen Receptor Cell Therapy Revenue by Type (2023-2028) & (USD Million)
Table 159. Middle East & Africa Chimeric Antigen Receptor Cell Therapy Revenue by Application (2017-2022) & (USD Million)
Table 160. Middle East & Africa Chimeric Antigen Receptor Cell Therapy Revenue by Application (2023-2028) & (USD Million)
Table 161. Middle East & Africa Chimeric Antigen Receptor Cell Therapy Revenue by Country (2017-2022) & (USD Million)
Table 162. Middle East & Africa Chimeric Antigen Receptor Cell Therapy Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Chimeric Antigen Receptor Cell Therapy Picture
Figure 2. Global Chimeric Antigen Receptor Cell Therapy Revenue Market Share by Type in 2021
Figure 3. Monotherapy
Figure 4. Combination Therapy
Figure 5. Chimeric Antigen Receptor Cell Therapy Revenue Market Share by Application in 2021
Figure 6. Acute Leukemia Picture
Figure 7. Non-hodgkin's Lymphoma Picture
Figure 8. Multiple Myeloma Picture
Figure 9. Transplant Rejection Picture
Figure 10. Other Picture
Figure 11. Global Chimeric Antigen Receptor Cell Therapy Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 12. Global Chimeric Antigen Receptor Cell Therapy Revenue and Forecast (2017-2028) & (USD Million)
Figure 13. Global Chimeric Antigen Receptor Cell Therapy Revenue Market Share by Region (2017-2028)
Figure 14. Global Chimeric Antigen Receptor Cell Therapy Revenue Market Share by Region in 2021
Figure 15. North America Chimeric Antigen Receptor Cell Therapy Revenue (USD Million) and Growth Rate (2017-2028)
Figure 16. Europe Chimeric Antigen Receptor Cell Therapy Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. Asia-Pacific Chimeric Antigen Receptor Cell Therapy Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. South America Chimeric Antigen Receptor Cell Therapy Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. Middle East and Africa Chimeric Antigen Receptor Cell Therapy Revenue (USD Million) and Growth Rate (2017-2028)
Figure 20. Chimeric Antigen Receptor Cell Therapy Market Drivers
Figure 21. Chimeric Antigen Receptor Cell Therapy Market Restraints
Figure 22. Chimeric Antigen Receptor Cell Therapy Market Trends
Figure 23. Amgen Inc Recent Developments and Future Plans
Figure 24. Autolus Therapeutics Plc Recent Developments and Future Plans
Figure 25. Beijing Immunochina Medical Science & Technology Co Ltd Recent Developments and Future Plans
Figure 26. Bellicum Pharmaceuticals Inc Recent Developments and Future Plans
Figure 27. Bristol-Myers Squibb Co Recent Developments and Future Plans
Figure 28. bluebird bio Inc Recent Developments and Future Plans
Figure 29. CARsgen Therapeutics Ltd Recent Developments and Future Plans
Figure 30. Celgene Corp Recent Developments and Future Plans
Figure 31. Cell Medica Ltd Recent Developments and Future Plans
Figure 32. Cellular Biomedicine Group Inc Recent Developments and Future Plans
Figure 33. Celularity Inc Recent Developments and Future Plans
Figure 34. Celyad SA Recent Developments and Future Plans
Figure 35. Daiichi Sankyo Co Ltd Recent Developments and Future Plans
Figure 36. Fosun Pharmaceutical AG Recent Developments and Future Plans
Figure 37. Gilead Sciences Inc Recent Developments and Future Plans
Figure 38. Guangzhou Anjie Biomedical Technology Co Ltd Recent Developments and Future Plans
Figure 39. Hangzhou Converd Co Ltd Recent Developments and Future Plans
Figure 40. Hebei Senlang Biotechnology Inc Ltd Recent Developments and Future Plans
Figure 41. HRAIN Biotechnology Co Ltd Recent Developments and Future Plans
Figure 42. Juno Therapeutics Inc Recent Developments and Future Plans
Figure 43. Kite Pharma Inc Recent Developments and Future Plans
Figure 44. Nanjing Legend Biotech Co Ltd Recent Developments and Future Plans
Figure 45. NantKwest Inc Recent Developments and Future Plans
Figure 46. Nkarta Inc Recent Developments and Future Plans
Figure 47. Novartis AG Recent Developments and Future Plans
Figure 48. Ono Pharmaceutical Co Ltd Recent Developments and Future Plans
Figure 49. Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Recent Developments and Future Plans
Figure 50. Sorrento Therapeutics Inc Recent Developments and Future Plans
Figure 51. Takara Bio Inc Recent Developments and Future Plans
Figure 52. Global Chimeric Antigen Receptor Cell Therapy Revenue Share by Players in 2021
Figure 53. Chimeric Antigen Receptor Cell Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 54. Global Top 3 Players Chimeric Antigen Receptor Cell Therapy Revenue Market Share in 2021
Figure 55. Global Top 10 Players Chimeric Antigen Receptor Cell Therapy Revenue Market Share in 2021
Figure 56. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 57. Global Chimeric Antigen Receptor Cell Therapy Revenue Share by Type in 2021
Figure 58. Global Chimeric Antigen Receptor Cell Therapy Market Share Forecast by Type (2023-2028)
Figure 59. Global Chimeric Antigen Receptor Cell Therapy Revenue Share by Application in 2021
Figure 60. Global Chimeric Antigen Receptor Cell Therapy Market Share Forecast by Application (2023-2028)
Figure 61. North America Chimeric Antigen Receptor Cell Therapy Sales Market Share by Type (2017-2028)
Figure 62. North America Chimeric Antigen Receptor Cell Therapy Sales Market Share by Application (2017-2028)
Figure 63. North America Chimeric Antigen Receptor Cell Therapy Revenue Market Share by Country (2017-2028)
Figure 64. United States Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Canada Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Mexico Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Europe Chimeric Antigen Receptor Cell Therapy Sales Market Share by Type (2017-2028)
Figure 68. Europe Chimeric Antigen Receptor Cell Therapy Sales Market Share by Application (2017-2028)
Figure 69. Europe Chimeric Antigen Receptor Cell Therapy Revenue Market Share by Country (2017-2028)
Figure 70. Germany Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. France Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. United Kingdom Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Russia Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Italy Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Asia-Pacific Chimeric Antigen Receptor Cell Therapy Sales Market Share by Type (2017-2028)
Figure 76. Asia-Pacific Chimeric Antigen Receptor Cell Therapy Sales Market Share by Application (2017-2028)
Figure 77. Asia-Pacific Chimeric Antigen Receptor Cell Therapy Revenue Market Share by Region (2017-2028)
Figure 78. China Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 79. Japan Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 80. South Korea Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 81. India Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 82. Southeast Asia Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 83. Australia Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 84. South America Chimeric Antigen Receptor Cell Therapy Sales Market Share by Type (2017-2028)
Figure 85. South America Chimeric Antigen Receptor Cell Therapy Sales Market Share by Application (2017-2028)
Figure 86. South America Chimeric Antigen Receptor Cell Therapy Revenue Market Share by Country (2017-2028)
Figure 87. Brazil Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 88. Argentina Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 89. Middle East and Africa Chimeric Antigen Receptor Cell Therapy Sales Market Share by Type (2017-2028)
Figure 90. Middle East and Africa Chimeric Antigen Receptor Cell Therapy Sales Market Share by Application (2017-2028)
Figure 91. Middle East and Africa Chimeric Antigen Receptor Cell Therapy Revenue Market Share by Country (2017-2028)
Figure 92. Turkey Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 93. Saudi Arabia Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 94. UAE Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 95. Methodology
Figure 96. Research Process and Data Source
Published By : GlobalInfoResearch
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
